TREATMENTS OF REFRACTORY CANCERS USING NA+/K+-ATPASE INHIBITORS

摘要

The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using NaSUP+/SUP/KSUP+/SUP-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain or proscillaridin, etc.).